Long-acting Injectable Cabotegravir/Rilpivirine Effective in a Small Patient Cohort With Virologic Failure on Oral Antiretroviral Therapy.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 37740255.
- Also identified by DOI 10.1093/cid/ciad511.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We report 12 patients with persistent viremia on oral antiretroviral therapy who were initiated on injectable cabotegravir/rilpivirine (iCAB/RPV) without oral lead-in. All patients achieved viral suppression without any virologic rebound. iCAB/RPV may be considered as an option for patients unable to maintain suppression on oral antiretroviral therapy.
Medical subject headings
- Anti-HIV Agents
- HIV Infections
- Pyridones
- Diketopiperazines